Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tarsus Pharmaceuticals (TARS) Non-Current Assets (2020 - 2025)

Tarsus Pharmaceuticals (TARS) has 6 years of Non-Current Assets data on record, last reported at $20.6 million in Q2 2025.

  • For Q2 2025, Non-Current Assets changed N/A year-over-year to $20.6 million; the TTM value through Jun 2025 reached $58.8 million, changed N/A, while the annual FY2024 figure was $20.3 million, 116.73% up from the prior year.
  • Non-Current Assets reached $20.6 million in Q2 2025 per TARS's latest filing, up from $20.3 million in the prior quarter.
  • Across five years, Non-Current Assets topped out at $20.6 million in Q2 2025 and bottomed at -$234.1 million in Q3 2022.
  • Average Non-Current Assets over 5 years is -$22.2 million, with a median of $3.0 million recorded in 2021.
  • Peak YoY movement for Non-Current Assets: tumbled 7142.06% in 2022, then soared 276.21% in 2023.
  • A 5-year view of Non-Current Assets shows it stood at $3.0 million in 2021, then decreased by 15.8% to $2.5 million in 2022, then skyrocketed by 276.21% to $9.4 million in 2023, then surged by 116.73% to $20.3 million in 2024, then increased by 1.38% to $20.6 million in 2025.
  • Per Business Quant database, its latest 3 readings for Non-Current Assets were $20.6 million in Q2 2025, $20.3 million in Q4 2024, and $8.6 million in Q1 2024.